Loading…

Moyamoya disease: A human model for chronic hypoperfusion and intervention in Alzheimer's disease

Introduction Chronic cerebral hypoperfusion has been considered the etiology for sporadic Alzheimer's disease (AD). However, no valid clinical evidence exists due to the similar risk factors between cerebrovascular disease and AD. Methods We used moyamoya disease (MMD) as a model of chronic hyp...

Full description

Saved in:
Bibliographic Details
Published in:Alzheimer's & dementia : translational research & clinical interventions 2022, Vol.8 (1), p.e12285-n/a
Main Authors: Zou, Xiang, Yuan, Yifan, Liao, Yujun, Jiang, Conglin, Zhao, Fan, Ding, Ding, Gu, Yuxiang, Chen, Liang, Chu, Ying‐Hua, Hsu, Yi‐Cheng, Liebig, Patrick Alexander, Xu, Bin, Mao, Ying
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Chronic cerebral hypoperfusion has been considered the etiology for sporadic Alzheimer's disease (AD). However, no valid clinical evidence exists due to the similar risk factors between cerebrovascular disease and AD. Methods We used moyamoya disease (MMD) as a model of chronic hypoperfusion and cognitive impairment, without other etiology interference. Results Based on the previous reports and preliminary findings, we hypothesized that chronic cerebral hypoperfusion could be an independent upstream crucial variable, resulting in AD, and induce pathological hallmarks such as amyloid beta peptide and hyperphosphorylated tau accumulation. Discussion Timely intervention with revascularisation would help reverse the brain damage with AD hallmarks and lead to cognitive improvement.
ISSN:2352-8737
2352-8737
DOI:10.1002/trc2.12285